Attovia Therapeutics Inc., an early-stage biopharmaceutical company focused on immune-mediated diseases with significant unmet need, is seeking to raise up to $212.5 million in a US initial public offering, according to multiple reports. The company’s IPO is aimed at generating capital to support its development activities as it advances candidate therapies in its target areas. Both outlets describe Attovia as Goldman-backed and characterize it as early-stage, indicating it is not yet a late-stage revenue-generating biotech. The reports do not specify additional financial terms such as the number of shares to be offered, the proposed price range, or the expected timeline. Overall, the coverage is consistent on the core details: Attovia is pursuing a US IPO and is targeting a maximum raise of $212.5 million, with its focus on immune-mediated conditions. Investors would typically look for further disclosures in the company’s registration materials regarding clinical progress, management, and risk factors as the IPO process moves forward.